North America Dystonia Drugs Market

North America Dystonia Drugs Market Size, Share & Industry Trends Analysis Report By Distribution Channel, By Route of Administration, By Type (GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs), By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-13835 Publication Date: February-2023 Number of Pages: 70
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The North America Dystonia Drugs Market would witness market growth of 4.8% CAGR during the forecast period (2022-2028).

Dystonia is classified according to three primary factors: the age at which symptoms manifest, the affected body regions, and the underlying reason. The likelihood that several body parts will be affected by dystonia is often proportional to the age of onset. The younger one is at the outset of symptoms, the greater the likelihood they may spread. In contrast, the greater the period in the beginning, the greater the likelihood that the disease will remain mild.

The neck (cervical dystonia or spasmodic torticollis), eyes (blepharospasm), jaw/mouth/lower face (oromandibular dystonia), vocal cords (laryngeal dystonia), or arms/legs might be affected by focal dystonia (limb dystonia). Other less common types of focal dystonias might involve abnormal stretching, bending, or twisting of the trunk (truncal dystonia), persistent contractions, and involuntary abdominal wall writhing (abdominal wall dystonia). Focal dystonia affects persons in their 40s and 50s more frequently and is commonly referred to as adult-onset dystonia. Around three times more women are impacted than men. Focal dystonias are typically classed as primary (idiopathic) and are not inherited.

The American healthcare system is a hub for innovation that creates and widely disseminates cutting-edge, life-improving therapies and provides healthcare consumers with a wide range of options. There are many advantages to the existing healthcare system. Also, the government is working on many areas where improvements may be made to lower prices, broaden access, raise quality, and improve Americans' health. HHS (Health and Human Services) aims to safeguard and provide accessible, high-quality healthcare equitably. The Department's activities are concentrated on lowering costs, enhancing the quality of healthcare services, assuring access to safe medical devices and medications, and expanding choice, affordability, and enrollment in high-quality healthcare coverage.

The US market dominated the North America Dystonia Drugs Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $317 Million by 2028. The Canada market is poised to grow at a CAGR of 6.8% during (2022 - 2028). Additionally, The Mexico market would witness a CAGR of 6.5% during (2022 - 2028).

Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on Type, the market is segmented into GABAergic Agents, Dopaminergic Agents, Anticonvulsants Drugs and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Dystonia Drugs Market is Estimated to reach $1.1 Billion by 2028, at a CAGR of 5.4%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Pfizer, Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., AbbVie, Inc., F. Hoffmann-La Roche Ltd., Ipsen Pharma Biotech SAS, Hameln Pharma Gmbh (Siegfried Group, LLP), Amneal Pharmaceuticals, Inc., Merz Pharma GmbH & Co. KGaA, and Wellona Pharma.

Scope of the Study

Market Segments Covered in the Report:

By Distribution Channel

  • Drug Stores & Retail Pharmacies
  • Hospital Pharmacies
  • Online Providers

By Route of Administration

  • Oral
  • Injectable

By Type

  • GABAergic Agents
  • Dopaminergic Agents
  • Anticonvulsants Drugs
  • Others

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Pfizer, Inc.
  • Novartis AG
  • Teva Pharmaceuticals Industries Ltd.
  • AbbVie, Inc.
  • F.Hoffmann-La Roche Ltd.
  • Ipsen Pharma Biotech SAS
  • Hameln Pharma Gmbh (Siegfried Group, LLP)
  • Amneal Pharmaceuticals, Inc.
  • Merz Pharma GmbH & Co. KGaA
  • Wellona Pharma
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo